As of 2025-11-29, the Relative Valuation of Halozyme Therapeutics Inc (HALO) is 123.05 USD. This relative valuation is based on P/E multiples. With the latest stock price at 71.40 USD, the upside of Halozyme Therapeutics Inc based on Relative Valuation is 72.3%.
The range of the Relative Valuation is 100.70 - 160.30 USD.
| Range | Selected | |
| Trailing P/E multiples | 19.8x - 24.8x | 22.3x |
| Forward P/E multiples | 22.2x - 34.0x | 28.1x |
| Fair Price | 100.70 - 160.30 | 123.05 |
| Upside | 41.0% - 124.5% | 72.3% |
| Date | P/E |
| 2025-11-28 | 14.02 |
| 2025-11-26 | 14.27 |
| 2025-11-25 | 14.30 |
| 2025-11-24 | 14.54 |
| 2025-11-21 | 13.82 |
| 2025-11-20 | 13.55 |
| 2025-11-19 | 13.80 |
| 2025-11-18 | 13.77 |
| 2025-11-17 | 13.86 |
| 2025-11-14 | 13.76 |
| 2025-11-13 | 13.98 |
| 2025-11-12 | 13.87 |
| 2025-11-11 | 13.78 |
| 2025-11-10 | 13.36 |
| 2025-11-07 | 13.40 |
| 2025-11-06 | 13.43 |
| 2025-11-05 | 13.42 |
| 2025-11-04 | 13.37 |
| 2025-11-03 | 13.00 |
| 2025-10-31 | 12.80 |
| 2025-10-30 | 12.70 |
| 2025-10-29 | 12.82 |
| 2025-10-28 | 12.85 |
| 2025-10-27 | 12.93 |
| 2025-10-24 | 12.99 |
| 2025-10-23 | 13.14 |
| 2025-10-22 | 12.92 |
| 2025-10-21 | 13.14 |
| 2025-10-20 | 13.06 |
| 2025-10-17 | 13.17 |
| 2025-10-16 | 13.14 |
| 2025-10-15 | 13.03 |
| 2025-10-14 | 13.09 |
| 2025-10-13 | 12.83 |
| 2025-10-10 | 12.59 |
| 2025-10-09 | 12.79 |
| 2025-10-08 | 12.81 |
| 2025-10-07 | 12.97 |
| 2025-10-06 | 13.15 |
| 2025-10-03 | 13.55 |
| 2025-10-02 | 14.08 |
| 2025-10-01 | 14.72 |
| 2025-09-30 | 14.41 |
| 2025-09-29 | 14.40 |
| 2025-09-26 | 14.49 |
| 2025-09-25 | 14.53 |
| 2025-09-24 | 14.86 |
| 2025-09-23 | 15.24 |
| 2025-09-22 | 15.38 |
| 2025-09-19 | 15.28 |